Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: Subgroup analysis of a randomized phase 3 trial

  1. Zinzani, P.L.
  2. Khuageva, N.K.
  3. Wang, H.
  4. Garicochea, B.
  5. Walewski, J.
  6. Van Hoof, A.
  7. Soubeyran, P.
  8. Caballero, D.
  9. Buckstein, R.
  10. Esseltine, D.-L.
  11. Theocharous, P.
  12. Enny, C.
  13. Zhu, E.
  14. Elsayed, Y.A.
  15. Coiffier, B.
Zeitschrift:
Journal of Hematology and Oncology

ISSN: 1756-8722

Datum der Publikation: 2012

Ausgabe: 5

Art: Artikel

DOI: 10.1186/1756-8722-5-67 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus